Publicacións en colaboración con investigadores/as de Hospital Universitario de Donostia (14)

2024

  1. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  2. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

2023

  1. Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis

    Annals of Surgical Oncology, Vol. 30, Núm. 12, pp. 7645-7652

  2. Oncological outcomes among young women with non-epithelial ovarian cancer: The YOC-Care study (Young Ovarian Cancer - Care)

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 915-921

  3. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

2022

  1. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network

    Cancers, Vol. 14, Núm. 8

  2. SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer

    International Journal of Gynecological Cancer, Vol. 32, Núm. 10, pp. 1236-1243

2021

  1. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

2019

  1. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2018

  1. Correction to: SEOM clinical guidelines for endometrial cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (29-37), 10.1007/s12094-017-1809-9)

    Clinical and Translational Oncology

  2. SEOM clinical guidelines for endometrial cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 29-37

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2008

  1. A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) trial

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 31, Núm. 5, pp. 481-487